Novel drug application shows improved survival for patients with relapsed and refractory acute myeloid leukemia
Relapsed/refractory acute myeloid leukemia (AML), a blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient's organ functions. A type of anti-tumor immunotherapy ...
Jul 18, 2024
0
0